Aigen Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aigen Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,538	Closed	-$2.07M	–	568
2025 Q3	$2.07M	Buy	+4,538	New	+$1.85M	0.32%	63
2025 Q1	–	Sell	-2,606	Closed	-$613K	–	742
2024 Q4	$613K	Buy	+2,606	New	+$685K	0.11%	277
2024 Q2	–	Sell	-2,827	Closed	-$422K	–	750
2024 Q1	$422K	Sell	2,827 -21,717	-88%	-$3.62M	0.09%	328
2023 Q4	$4.7M	Buy	+24,544	New	+$4.18M	0.84%	7
2023 Q3	–	Sell	-26,604	Closed	-$5.05M	–	803
2023 Q2	$5.05M	Buy	26,604 +11,978	+82%	+$2.37M	0.75%	14
2023 Q1	$2.93M	Buy	14,626 +7,767	+113%	+$1.63M	0.4%	60
2022 Q4	$1.63M	Buy	6,859 +4,936	+257%	+$1.05M	0.23%	123
2022 Q3	$385K	Buy	+1,923	New	+$367K	0.06%	356
2022 Q2	–	Sell	-3,420	Closed	-$558K	–	515
2022 Q1	$558K	Buy	+3,420	New	+$521K	0.1%	264
2021 Q3	–	Sell	-3,283	Closed	-$557K	–	459
2021 Q2	$557K	Buy	+3,283	New	+$481K	0.1%	217

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Aigen Investment Management's ALNY Position: Q4 2025 in Review

Aigen Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 4,538 shares — an estimated $2.07M sold.

Aigen Investment Management first reported a position in ALNY in Q2 2021 and held it in 10 quarters. The position peaked at $5.05M in Q2 2023. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Aigen Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Aigen Investment Management sold 4,538 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $2.07M.
Aigen Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 10 quarters.
Aigen Investment Management's Alnylam Pharmaceuticals position peaked at $5.05M in Q2 2023.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Aigen Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.